Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

60275 1492790397HCLSReviewGreeceApril2017.pdf
Energy Boardroom

Analysts: Biogen's second long-acting hemophilia med headed for blockbuster strata

09.06.2014 / Fierce Pharma

With Friday's FDA nod for Eloctate, Biogen Idec won approval for its second long-acting hemophilia treatment this year. But while both will shake up their respective markets, this one–a hemophilia A treatment–will be where the money is.

Cover_HCLS_GREECE LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: